Biogen Idec Senior VP International Business on Expanding Opportunities And Lessons Learned In Asia
This article was originally published in PharmAsia News
Executive Summary
Biogen Idec's strategy in emerging markets is not likely to change under the company's new CEO George Scangos, according to Senior VP International Business Gunther Winkler
You may also be interested in...
"With A Molecule That Is A Million Times Larger Than A Small Molecule, So Many Things Can Go Wrong," Says Biogen Idec Asia Operations Head Gunther Winkler
Gunther Winkler, Biogen Idec's Senior Vice President, International Business, is responsible for expanding the company's Asia operations. Winkler, a close watcher of biosimilars regulations being adapted by various countries, is skeptical about the safety of copied biotech drugs and therefore calls for sufficient caution on the approval mechanism for such drugs. In an interview with PharmAsia News' India bureau, Gunther Winkler spells out the company's ambitions in Asia, which includes research on products that could be relevant to local populations.
Biogen Set For Avonex Launch In India, But Concerned About Biosimilars Regulations
MUMBAI - Big Pharma has been increasingly attracted to the Indian market, but now big biotechs like Biogen Idec are also expanding their presence to make the most of the growth opportunities
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).